AstraZeneca ROE 2006-2018 | AZN

Current and historical return on equity (ROE) values for AstraZeneca (AZN) over the last 10 years. Return on equity can be defined as the amount of net income returned as a percentage of shareholders equity. Return on equity measures a corporation's profitability by revealing how much profit a company generates with the money shareholders have invested. AstraZeneca ROE for the three months ending September 30, 2018 was 27.32%.
AstraZeneca ROE - Return on Equity Historical Data
Date TTM Net Income Shareholder's Equity Return on Equity
2018-09-30 $2.42B $13.54B 16.41%
2018-06-30 $2.68B $14.27B 17.57%
2018-03-31 $2.80B $14.57B 18.07%
2017-12-31 $3.00B $16.64B 19.27%
2017-09-30 $3.54B $15.45B 22.74%
2017-06-30 $3.87B $15.41B 25.06%
2017-03-31 $3.39B $14.78B 21.96%
2016-12-31 $3.50B $16.67B 22.00%
2016-09-30 $2.47B $14.91B 15.06%
2016-06-30 $2.22B $15.39B 13.08%
2016-03-31 $2.92B $16.64B 16.50%
2015-12-31 $2.83B $18.51B 15.89%
2015-09-30 $1.70B $17.37B 9.39%
2015-06-30 $1.18B $18.30B 6.26%
2015-03-31 $1.28B $16.96B 6.47%
2014-12-31 $1.23B $19.65B 5.90%
2014-09-30 $1.03B $20.47B 4.72%
2014-06-30 $2.02B $22.05B 8.96%
2014-03-31 $2.05B $21.48B 8.95%
2013-12-31 $2.56B $23.25B 11.04%
2013-09-30 $4.59B $23.45B 19.67%
2013-06-30 $4.85B $23.41B 21.07%
2013-03-31 $5.63B $22.49B 24.75%
2012-12-31 $6.24B $23.95B 27.69%
2012-09-30 $6.23B $22.26B 27.77%
2012-06-30 $8.19B $22.23B 35.79%
2012-03-31 $8.71B $21.72B 37.39%
2011-12-31 $9.99B $23.47B 42.52%
2011-09-30 $10.13B $24.15B 43.14%
2011-06-30 $8.21B $23.82B 35.65%
2011-03-31 $8.21B $22.55B 36.27%
2010-12-31 $8.08B $23.41B 36.36%
2010-09-30 $8.01B $22.31B 37.13%
2010-06-30 $8.57B $22.27B 41.04%
2010-03-31 $8.16B $20.89B 41.22%
2009-12-31 $7.53B $20.82B 40.78%
2009-09-30 $7.22B $19.55B 41.78%
2009-06-30 $6.84B $17.94B 41.68%
2009-03-31 $6.75B $15.53B 42.42%
2008-12-31 $6.11B $16.06B 38.90%
2008-09-30 $6.14B $16.11B 39.90%
2008-06-30 $5.75B $15.97B 50.54%
2008-03-31 $5.53B $14.72B 49.84%
2007-12-31 $5.58B $14.78B 51.31%
2007-09-30 $5.75B $0.00B 52.19%
2007-06-30 $6.00B $14.85B 40.86%
2007-03-31 $6.20B $13.91B 42.19%
2006-12-31 $6.06B $15.30B 41.45%
2006-09-30 $5.85B $14.68B 41.16%
2006-06-30 $5.48B $14.91B 39.59%
2006-03-31 $5.10B $13.62B 37.81%
2005-12-31 $4.72B $13.60B 35.00%
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $103.621B $22.465B
AstraZeneca PLC is one of the top five pharmaceutical companies in the world based on sales and is a therapeutic leader in cardiovascular, gastrointestinal, oncology, anesthesia including pain management, central nervous system (CNS) and respiratory products. They are engaged in the research, development, manufacture and marketing of ethical (prescription) pharmaceuticals and agricultural products, and the supply of healthcare services.
Stock Name Country Market Cap PE Ratio
Johnson & Johnson (JNJ) United States $390.684B 18.32
Pfizer (PFE) United States $262.581B 14.80
Novartis AG (NVS) Switzerland $204.469B 17.47
Merck (MRK) United States $201.378B 17.45
AbbVie (ABBV) United States $134.913B 11.98
Eli Lilly (LLY) United States $119.915B 21.08
Sanofi (SNY) France $111.886B 13.85
Novo Nordisk (NVO) Denmark $108.835B 17.67
GlaxoSmithKline (GSK) United Kingdom $101.752B 13.68
Bristol-Myers Squibb (BMY) United States $86.262B 14.21